Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C, Mallesara G, Guminski A, Lee A, Stockler MR, Hickey A, Eu P, Joshua AM, Crumbaker M, Nguyen A.
Emmett L, et al. Among authors: sharma s.
Ther Adv Med Oncol. 2023 Mar 1;15:17588359231156392. doi: 10.1177/17588359231156392. eCollection 2023.
Ther Adv Med Oncol. 2023.
PMID: 36872949
Free PMC article.